"We are pleased to announce the release of our new semi-automated CalECG v3 solution for the analysis of ECGs," said CoreLab Partners’ president and chief executive officer, Dr. Mike Woehler. "This new application represents our commitment to advancing technologies in the cardiac safety market sector and complements our established processes in our proprietary WebHeart® technology platform."

The well-known AMPS CalECG application, originally designed for the on-screen measurement of ECG signals in the context of pharmaceutical trials, is capable of handling digital ECGs, seamlessly interfacing with several types of formats. The recently introduced version three of CalECG includes the new powerful measurement algorithm, Bravo, as well as a diagnostic module assisting the user in the determination of important caliper positions.

CoreLab Partners has also licensed the full set of AMPS Heart Rate Variability tools (WinHRV), which has been extensively used in the academic domain for the assessment of autonomic nervous systems changes associated with both clinical and drug-induced conditions.

Fabio Badilini, PhD, FACC, chief scientist and AMPS founder commented: "It is the first time that WinHRV will be implemented within a core lab organization, a sign that the effects of central nervous system are becoming an important facet of a number of new compounds. By adopting the WinHRV technology, CoreLab Partners continues to prove itself as a leading edge provider of new technologies to the industry."